Chinook Therapeutics (KDNY) 10-Q 2 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 26, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	ADRO
Entity Registrant Name	ADURO BIOTECH, INC.
Entity Central Index Key	1,435,049
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		74,612,449

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 183,815	$ 74,932
Short-term marketable securities	193,428	272,500
Accounts receivable	3,434	1,138
Prepaid expenses and other current assets	4,278	6,194
Total current assets	384,955	354,764
Long-term marketable securities		14,474
Property and equipment, net	26,360	26,384
Goodwill	8,318	7,658
Intangible assets, net	29,946	27,827
Restricted cash	468	468
Deferred tax assets	5,047	6,319
Other assets	8,465	717
Total assets	463,559	438,611
Current liabilities:
Accounts payable	2,813	2,206
Accrued clinical trial and manufacturing expenses	4,048	4,777
Accrued expenses and other liabilities	7,073	8,597
Deferred revenue	14,945	15,052
Total current liabilities	28,879	30,632
Deferred rent	7,778	6,786
Contingent consideration	6,044	4,032
Deferred revenue	155,556	162,963
Deferred tax liabilities	6,307	5,869
Other long term liabilities	1,255	1,109
Total liabilities	205,819	211,391
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2017 and December 31, 2016; and zero shares issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.0001 par value; 300,000,000 shares authorized June 30, 2017 and December 31, 2016; and 73,676,295 and 67,918,246 shares issued and outstanding at June 30, 2017 and December 31, 2016	7	7
Additional paid-in capital	490,336	420,897
Accumulated other comprehensive benefit (loss)	608	(1,684)
Accumulated deficit	(233,211)	(192,000)
Total stockholders’ equity	257,740	227,220
Total liabilities and stockholders’ equity	$ 463,559	$ 438,611

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock par value per share	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value per share	$ 0.0001	$ 0.0001
Common stock shares authorized	300,000,000	300,000,000
Common stock shares issued	73,676,295	67,918,246
Common stock shares outstanding	73,676,295	67,918,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Collaboration and license revenue	$ 5,876	$ 38,938	$ 9,648	$ 42,921
Grant revenue	41	41	41	88
Total revenue	5,917	38,979	9,689	43,009
Operating expenses:
Research and development	21,440	26,882	42,011	47,809
General and administrative	8,245	8,700	16,523	17,699
Amortization of intangible assets	136	140	268	277
Total operating expenses	29,821	35,722	58,802	65,785
(Loss) income from operations	(23,904)	3,257	(49,113)	(22,776)
Interest income, net	780	520	1,430	974
Other loss, net	(64)	(9)	(68)	(31)
(Loss) income before income tax	(23,188)	3,768	(47,751)	(21,833)
Income tax (benefit) provision	(3,788)	1,472	(6,540)	4,698
Net (loss) income	$ (19,400)	$ 2,296	$ (41,211)	$ (26,531)
Net (loss) income per common share, basic	$ (0.27)	$ 0.04	$ (0.59)	$ (0.41)
Net (loss) income per common share, diluted	$ (0.27)	$ 0.03	$ (0.59)	$ (0.41)
Shares used in computing net loss per common share, basic	71,101,336	64,434,903	69,679,746	64,138,737
Shares used in computing net loss per common share, diluted	71,101,336	71,473,807	69,679,746	64,138,737

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (19,400)	$ 2,296	$ (41,211)	$ (26,531)
Other comprehensive (loss) income, net of tax:
Unrealized gain on marketable securities	25	69	2	220
Foreign currency translation adjustments	1,925	(619)	2,290	511
Comprehensive (loss) income	$ (17,450)	$ 1,746	$ (38,919)	$ (25,800)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash Flows from Operating Activities
Net loss	$ (41,211)	$ (26,531)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,659	739
Amortization of intangible assets	268	277
Accretion of discounts and amortization of premiums on marketable securities	497	1,045
Stock-based compensation	7,985	7,068
Excess tax benefit from stock-based compensation		(2,185)
Gain from remeasurement of fair value of contingent consideration	1,636	(317)
Loss on disposal of property and equipment	5
Deferred income tax	1,272
Changes in operating assets and liabilities:
Accounts receivable	(2,238)	3,462
Prepaid expenses and other assets	(5,832)	(9,074)
Restricted cash		(468)
Accounts payable	607	(2,814)
Deferred revenue	(7,514)	(7,542)
Accrued clinical trial and manufacturing expenses	(576)	8,356
Accrued expenses and other liabilities	(670)	2,094
Net cash used in operating activities	(44,112)	(25,890)
Cash Flows from Investing Activities
Purchase of marketable securities	(140,626)	(244,250)
Proceeds from maturities of marketable securities	233,678	233,108
Purchase of property and equipment	(1,453)	(10,536)
Net cash provided by (used in) investing activities	91,599	(21,678)
Cash Flows from Financing Activities
Proceeds from employee stock purchase plan	494	514
Excess tax benefit from stock-based compensation		2,185
Proceeds from exercise of stock options and warrants	435	351
Proceeds from issuance of common stock, net of offering costs	60,467
Net cash provided by financing activities	61,396	3,050
Net increase (decrease) in cash and cash equivalents	108,883	(44,518)
Cash and cash equivalents at beginning of period	74,932	150,456
Cash and cash equivalents at end of period	183,815	105,938
Supplemental Disclosure of Cash Flow Information
Cash paid for taxes	850	8,600
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchase of property and equipment in accounts payable and accrued liabilities	$ 219	$ 4,135

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Business	1. Organization and Nature of Business Aduro Biotech, Inc., and its wholly-owned subsidiaries, or the Company, is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases, including cancer. The Company is located in Berkeley, California and its wholly-owned subsidiary, Aduro Biotech Holdings, Europe B.V., or Aduro Biotech Europe, is based in the Netherlands. The Company operates in one business segment. The Company believes its three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth. Product candidates from the Company’s LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes

Basis of Presentation, Use of E

Basis of Presentation, Use of Estimates and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation, Use of Estimates and Recent Accounting Pronouncements	2. Basis of Presentation, Use of Estimates and Recent Accounting Pronouncements Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and follow the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or for any other interim period or for any other future year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in our Annual Report on Form 10-K filed with the SEC. The consolidated financial statements include the accounts of Aduro Biotech, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical trial accruals, contingent consideration, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from these estimates. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued Auditing Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which reduces the complexity when applying the guidance for identifying performance obligations and improves the operability and understandability of the license implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which amends the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach with the cumulative effect of initially applying the new standard recognized at the date of initial application and providing certain additional disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted for annual reporting periods beginning after December 15, 2016. The Company plans to adopt the new standard effective January 1, 2018 and has not made the decision as to which adoption method it will utilize. The Company’s final determination will depend on the significance of the impact of the new standard on the Company’s financial results. The Company has completed the initial evaluation of the adoption of the new standard. This included the determination of whether the counterparty in its existing collaboration agreements met the definition of a customer and whether such agreements would be within the scope of the new standard. As a result, certain of the Company’s collaboration agreements are in scope and the Company is currently determining the impact that these agreements may have on its financial results. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments--Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company has evaluated the impact of this guidance and has concluded that adoption of the standard will not have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and, (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018 and requires modified retrospective application. Early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326). The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. The standard is effective for fiscal years and interim periods beginning after December 15, 2019. Early adoption is permitted for all periods beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows. The standard is effective for fiscal years and interim periods beginning after December 15, 2017. The standard should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company has evaluated the impact of this guidance and has concluded that the adoption of the standard will not have a material impact on its Consolidated Statement of Cash Flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that the statement of cash flows explains the change during the period in the total cash, cash equivalents, and restricted cash. The standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. This standard should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company plans to adopt this standard on January 1, 2018 utilizing the required retrospective transition method. The adoption of ASU 2016-18 on January 1, 2018 will change the presentation and classification of restricted cash in our Consolidated Statement of Cash Flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 provides clarity and reduces the complexity of applying the guidance in Topic 718, Compensation – Stock Compensation, to a change to the terms or conditions of a share-based payment award. This standard is effective for annual periods beginning after December 15, 2017. The Company is currently in the process of evaluating the impact that the standard will have on its consolidated financial statements. Recently Adopted Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeitures. Formerly, these excess tax benefits were recognized in additional paid-in capital and tax deficiencies (to the extent there were previous tax benefits) were recognized as an offset to accumulated excess tax benefits. If no previous tax benefit existed, the deficiencies were recognized in the income statement as an increase to income tax expense. The changes require all excess tax benefits and tax deficiencies related to share-based payments be recognized as income tax expense or benefit in the income statement. Gross excess tax benefits in the cash flow statement have also changed from the prior presentation as a financing activity to being classified as an operating activity. The excess tax benefits are no longer included in the assumed proceeds of the diluted EPS calculation, which results in stock-based awards being more dilutive. Lastly, the Company elected to continue to estimate forfeitures based on historical data and recognizes forfeiture compensation expense over the vesting period of the award. This standard is effective prospectively for annual reporting periods, and interim periods therein, beginning after December 15, 2016. The Company adopted this ASU on January 1, 2017 which resulted in the recognition of excess tax benefits within the Condensed Consolidated Statements of Operations rather than paid-in capital of $1.8 million for the six months ended June 30, 2017.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The carrying amounts of certain of the Company’s financial instruments, including cash equivalents, accounts receivable and accounts payable approximate their fair values due to their short maturities. Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value, and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows: Level 1 —Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2 —Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 —Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. The Company’s cash equivalents, which include money market funds, are classified as Level 1 because they are valued using quoted market prices. The Company’s marketable securities consist of available-for-sale securities and are generally classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. In certain cases where there is limited activity or less transparency around the inputs to valuation, securities are classified as Level 3. Level 3 liabilities consist of the contingent consideration liability. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 52,650 $ — $ — $ 52,650 U.S. government and agency securities — 116,114 — 116,114 Corporate debt securities — 71,222 — 71,222 Commercial paper — 124,235 — 124,235 Total $ 52,650 $ 311,571 $ — $ 364,221 Financial Liabilities: Contingent consideration related to acquisition $ — $ — $ 6,044 $ 6,044 Total $ — $ — $ 6,044 $ 6,044 December 31, 2016 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 54,318 $ — $ — $ 54,318 U.S. government and agency securities — 166,800 — 166,800 Corporate debt securities — 77,880 — 77,880 Commercial paper — 49,643 — 49,643 Total $ 54,318 $ 294,323 $ — $ 348,641 Financial Liabilities: Contingent consideration related to acquisition $ — $ — $ 4,032 $ 4,032 Total $ — $ — $ 4,032 $ 4,032 The acquisition-date fair value of the contingent consideration liability represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value of the contingent consideration is based on the Company’s probability-weighted discounted cash flow assessment that considers probability and timing of future payments. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones. Changes in the fair value of the liability for contingent consideration, except for the impact of foreign currency, will be recognized as research and development expense in the condensed consolidated statements of operations until settlement. The Company did not have any financial assets and liabilities measured at fair value on a non-recurring basis as of June 30, 2017 and December 31, 2016. There were no transfers between the fair value measurement category levels during any of the periods presented. The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands): Contingent Consideration Balance at December 31, 2016 $ 4,032 Net change in fair value upon remeasurement 1,636 Foreign currency impact on contingent consideration 376 Balance at June 30, 2017 $ 6,044 The following tables summarize the estimated value of the Company’s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands): June 30, 2017 Amortized cost Unrealized gains Unrealized losses Estimated Fair Value Cash and cash equivalents: Cash $ 13,022 $ — $ — $ 13,022 Money market funds 52,650 — — 52,650 U.S. government and agency securities 40,735 1 (1 ) 40,735 Commercial paper 77,408 — — 77,408 Total cash and cash equivalents $ 183,815 $ 1 $ (1 ) $ 183,815 Marketable securities: U.S. government and agency securities $ 75,457 $ — $ (78 ) $ 75,379 Corporate debt securities 71,284 — (62 ) 71,222 Commercial paper 46,827 — — 46,827 Total marketable securities $ 193,568 $ — $ (140 ) $ 193,428 December 31, 2016 Amortized cost Unrealized gains Unrealized losses Estimated Fair Value Cash and cash equivalents: Cash $ 13,265 $ — $ — $ 13,265 Money market funds 54,318 — — 54,318 Commercial paper 7,349 — — 7,349 Total cash and cash equivalents $ 74,932 $ — $ — $ 74,932 Marketable securities: U.S. government and agency securities $ 166,854 $ 7 $ (61 ) $ 166,800 Corporate debt securities 77,967 — (87 ) 77,880 Commercial paper 42,294 — 42,294 Total marketable securities $ 287,115 $ 7 $ (148 ) $ 286,974 The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities by contractual maturity are summarized below as of June 30, 2017 (in thousands): Amortized cost Estimated Fair Mature in one year or less $ 193,568 $ 193,428 Total available-for-sale marketable securities $ 193,568 $ 193,428

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2017
Balance Sheet Components [Abstract]
Balance Sheet Components	4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2017 2016 Lab equipment $ 6,571 $ 5,379 Computer and office equipment 1,816 1,755 Furniture and fixtures 1,731 1,479 Leasehold improvements 17,968 17,473 Construction in progress 3,588 3,930 Total property and equipment 31,674 30,016 Less: accumulated depreciation and amortization (5,314 ) (3,632 ) Property and equipment, net $ 26,360 $ 26,384 Depreciation and amortization expense was $833,000 and $382,000 for the three months ended June 30, 2017 and 2016, respectively, and $1.7 million and $739,000 for the six months ended June 30, 2017 and 2016, respectively. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): June 30, December 31, 2017 2016 Compensation and related benefits $ 3,101 $ 4,228 Professional and consulting services 1,586 1,168 Deferred rent, current portion 421 331 Accrued research expense 775 489 Income tax payable — 806 Other 1,190 1,575 Total accrued expenses and other liabilities $ 7,073 $ 8,597

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets Goodwill The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2016 $ 7,658 Foreign currency translation adjustment 660 Balance at June 30, 2017 $ 8,318 Intangible assets The gross carrying amounts and net book value of our intangible assets were as follows (in thousands): June 30, 2017 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: License agreement $ 11,297 $ 941 $ 10,356 Total intangible assets with finite lives 11,297 941 10,356 Acquired IPR&D assets 19,590 — 19,590 Total intangible assets $ 30,887 $ 941 $ 29,946 December 31, 2016 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: License agreement $ 10,400 $ 607 $ 9,793 Total intangible assets with finite lives 10,400 607 9,793 Acquired IPR&D assets 18,034 — 18,034 Total intangible assets $ 28,434 $ 607 $ 27,827 Intangible assets are carried at cost less accumulated amortization. The license agreement is being amortized over a period of 20 years and the amortization expense is recorded in operating expenses. The increase in the gross carrying amount of intangible assets as of June 30, 2017 compared to December 31, 2016 reflected a positive impact of foreign currency exchange which was primarily due to the strengthening of the Euro against the U.S. dollar. Amortization expense was $136,000 and $140,000 for the three months ended June 30, 2017 and 2016, respectively and $268,000 and $277,000 for the six months ended June 30, 2017 and 2016, respectively. Based on finite-lived intangible assets recorded as of June 30, 2017, the estimated future amortization expense is as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2017 (remaining six months) $ 282 2018 565 2019 565 2020 565 2021 565

Collaboration Agreements

Collaboration Agreements	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaboration Agreements	6. Collaboration Agreements Novartis Agreement In March 2015, the Company entered into a collaboration and license agreement with Novartis Pharmaceuticals Corporation, or Novartis, pursuant to which the Company is collaborating worldwide with Novartis regarding the development and potential commercialization of product candidates containing an agonist of the molecular target known as STING in the field of oncology, including immuno-oncology and cancer vaccines. Under this agreement, or the Novartis Agreement, the Company granted Novartis a co-exclusive license to develop such products worldwide, an exclusive license to commercialize such products outside the United States and a non-exclusive license to support the Company in commercializing such products in the United States if it requests such support. The collaboration is guided by a joint steering committee with each party having final decision making authority regarding specified areas of development or commercialization. Under the Novartis Agreement, the Company received an upfront payment of $200.0 million in April 2015. During the second quarter of 2016, the Company earned a $35.0 million development milestone upon initiation of a Phase 1 trial for the first STING product candidate, ADU-S100, and recognized the payment as revenue in the period. The Company is also eligible to receive up to an additional $215.0 million in development milestones and up to an additional $250.0 million in regulatory approval milestones. The Company is responsible for 38% of the joint development costs worldwide and Novartis is responsible for the remaining 62% of the joint development costs worldwide. The Company will also receive 50% of gross profits on sales of any products commercialized pursuant to this collaboration in the United States and 45% of gross profits for specified European countries and Japan. For each of these profit share countries, each party will be responsible for its respective commercial sharing percentage of all joint commercialization costs incurred in that country. For all other countries where the Company is not sharing profits, Novartis will be responsible for all commercialization costs and will pay the Company a royalty in the mid-teens on all net sales of product sold by Novartis, its affiliates and sublicensees, with such percentage subject to reduction post patent and data exclusivity expiration and subject to reduction, capped at a specified percentage, for royalties payable to third party licensors. Novartis’ royalty obligation will run on a country-by-country basis until the later of expiration of the last valid claim covering the product, expiration of data exclusivity for the product or 12 years after first commercial sale of the product in such country. With respect to the United States, specified European countries and/or Japan, the Company may elect for such region to either reduce by 50% or to eliminate in full the Company’s development and commercialization cost sharing obligation. If the Company elects to reduce its cost sharing percentage by 50% in any such region, then its profit share in such region will also be reduced by 50%. If the Company elects to eliminate its development cost sharing obligation, then such region will be removed from the profit share, and instead Novartis will owe the Company royalties on any net sales of product for such region, as described above. The Company recognizes revenue from collaboration, license or research arrangements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collection is reasonably assured. The Company has determined that the license does not have stand-alone value separable from the co-development services to be performed under the agreement, with the Company participating in the research and development services. As a result, the Company recognizes revenue from the $200.0 million upfront fee received on a straight-line basis over its estimated performance period of 13.5 years, commencing in July 2015, the date of the Joint Steering Committee’s approval of the research and development plan. Changes in the estimated period of performance will be accounted for prospectively as a change in estimate. The Company will recognize substantive milestone payments in their entirety in the period in which the milestone is achieved. Non-substantive milestone payments will be recognized on a straight-line basis over the remaining performance period. Costs associated with co-development activities performed under the agreement are included in research and development expenses in the accompanying condensed consolidated statements of operations. Reimbursement of research and development costs by Novartis is included in collaboration and license revenue. The Company will recognize revenue from the sale of any products commercialized pursuant to this collaboration in the United States, will retain 50% of the gross profits from such sales, and will pay the remaining 50% of the gross profits to Novartis. The Company will receive from Novartis 45% of gross profits for specified European countries and Japan. Profit sharing payments made to or received from Novartis are aggregated by product by territory and are reported as expenses or revenues, as applicable. For the three months ended June 30, 2017 and 2016, the Company recognized $3.8 million and $3.7 million, respectively, and for the six months ended June 30, 2017 and 2016, the Company recognized $7.5 million and $7.4 million, respectively, in revenue from its collaboration with Novartis primarily related to amortization of the upfront fee. The remaining balance of the upfront fees of $170.4 million is included in deferred revenue at June 30, 2017. Janssen ADU-214 Agreement In November 2014, the Company entered into a Research and License Agreement, or the Janssen ADU-214 Agreement, with Janssen Biotech Inc., or Janssen, a wholly owned subsidiary of Johnson & Johnson Development Corporation, to develop a drug for the treatment of lung cancer. Under the terms of the Janssen ADU-214 Agreement, the Company granted Janssen an exclusive, worldwide license to research, develop, manufacture, use, sell and otherwise exploit products containing ADU-214 for any and all uses. Janssen has agreed not to administer or cause to be administered ADU-214 in humans in clinical trials for the treatment of pancreatic cancer or mesothelioma. The Company was responsible for certain research and development activities from the effective date of the agreement until investigational new drug application, or IND, approval which occurred in the fourth quarter of 2015. Since the inception of the Janssen ADU-214 Agreement through June 30, 2017, the Company received an upfront license fee of $30.0 million and substantive and non-substantive milestone payments of $21.0 million upon completion of various development activities. Under the terms of the Janssen ADU-214 Agreement, the Company is eligible to receive future contingent payments up to a total of $766.0 million composed of development milestones through completion of all Phase 3 clinical trials, as well as regulatory and commercial milestones. The contingent payments are triggered upon the activities expected to be undertaken by Janssen. The Company is eligible to receive royalties on any net sales of licensed products by Janssen, its affiliates and sublicensees at a rate ranging from high-single digits to low teens based on the aggregate annual net sales of licensed products worldwide and based on the country of sale. The upfront license fee of $30.0 million was recognized on a straight-line basis from the effective date of the agreement through October 2015. In addition, the Company recognized milestone payments of $21.0 million in 2015 as all performance obligations were achieved. Janssen ADU-741 and GVAX Prostate Agreements In May 2014, the Company entered into a Research and License Agreement, or the Janssen ADU-741 Agreement, and a GVAX Prostate License Agreement, or Janssen GVAX Prostate Agreement, with Janssen to collaborate on the development of a drug for the treatment of prostate cancer. Under the terms of the Janssen ADU-741 Agreement, the Company granted Janssen an exclusive, worldwide license to research, develop, manufacture, use, sell and otherwise exploit products containing ADU-741 for any and all uses. The Company was responsible for certain research and development activities from the effective date of the agreement until IND approval which occurred in the fourth quarter of 2015. Since the inception of the Janssen ADU-741 Agreement through June 30, 2017, the Company received an upfront payment of $12.0 million and substantive and non-substantive milestone payments of $10.0 million upon completion of certain development activities. Under the terms of the Janssen ADU-741 Agreement, the Company is eligible to receive future contingent payments up to a total of $343.0 million composed of development milestones through completion of all Phase 3 clinical trials, as well as regulatory and commercial milestones. The contingent payments are triggered upon the activities expected to be undertaken by Janssen. The Company is eligible to receive royalties on net sales of licensed products by Janssen, its affiliates and sublicensees at a rate ranging from mid-single digits to low teens based on aggregate annual net sales and based on the country of sale. Under the Janssen GVAX Prostate Agreement, the Company granted Janssen an exclusive worldwide license to research, develop, manufacture, use, sell and otherwise exploit products containing GVAX Prostate for any and all uses. The Company received an upfront payment of $500,000 in May 2014 and is eligible to receive an additional $2.0 million on the achievement of a specified commercial milestone. In addition, the Company is eligible to receive royalties in the high single digits based on net sales of the product. The upfront fees received totaling $12.5 million were recognized on a straight-line basis from the effective date of the agreements through October 2015. In addition, the Company recognized milestone payments of $10.0 million in 2015 as all performance obligations were achieved. Merck License Agreement In connection with the acquisition of Aduro Biotech Europe in October 2015, the Company became party to an agreement with Merck Sharp & Dohme Corp., or Merck. The agreement sets forth the parties’ respective obligations for development, commercialization, regulatory and manufacturing and supply activities for antibody product candidates. The Company identified the following performance deliverables under the agreement: 1) the license, 2) the obligation to provide research activities and 3) the obligation to participate on a Joint Research Committee. The Company is eligible to receive future contingent payments, including up to $310.0 million in potential development milestone payments, and up to $135.0 million in commercial and net sales milestones for a product candidate. In addition, the Company is eligible to receive royalties in the mid-single digits to low teens based on net sales of the product. The Company considered the provisions of the multiple-element arrangement guidance in determining how to recognize the total consideration of the agreement. The Company determined that none of the deliverables have standalone value; all of these obligations will be delivered throughout the estimated period of performance and therefore are accounted for as a single unit of accounting. The Company determined that all of the future contingent payments meet the definition of a milestone. Accordingly, revenue for the achievement of these milestones will be recognized in the period when the milestone is achieved and collectability is reasonably assured . Genmab Agreement In February 2015, Aduro Biotech Europe entered into a co-development and commercialization agreement with Genmab to evaluate five DuoBody product candidates targeting immune checkpoints. Genmab and Aduro Biotech Europe will contribute panels of antibodies for the creation of bispecific antibody products using Genmab’s DuoBody platform. If the companies jointly select a product candidate for clinical development, development costs will be shared equally, with each party retaining a 50% share of the product rights. If one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the parties to opt out of joint development at key points in each product’s clinical development.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Leases The Company moved into its new corporate office and laboratory facility located in Berkeley, California in August, 2016. The Company’s offices are leased pursuant to an Office/Laboratory Lease that was entered into in September 2015, or the Heinz Lease. The Company began incurring rent expense when the landlord delivered possession of the facility to the Company in March 2016. Initially, the Heinz Lease was for approximately 56,000 square feet with an option for the Company to lease the remainder of the space within the facility. During the second quarter of 2016, the Company amended the lease to include approximately 7,000 additional square feet and on June 30, 2016 the Company exercised its option for approximately 41,000 additional square feet, representing the remaining space within the facility. The Heinz Lease had an initial term of twelve years, which was extended to approximately thirteen and a half years as a result of the option exercised on June 30, 2016. The Company has the right to further extend the Heinz Lease term for up to two renewal terms of five years each, provided that the rental rate would be subject to market adjustment at the beginning of each renewal term. The Company continues to lease its former office and research and development facility in Berkeley, California, under a non-cancelable operating lease, or the Bancroft Lease. In February 2015, the Company amended the Bancroft Lease agreement to increase the total square footage to approximately 25,000 square feet and extended the term of the Bancroft Lease to expire on December 31, 2018. The Bancroft Lease also contains an option to extend the lease for an additional two years. The Company has transitioned the entirety of its Berkeley operations to its Heinz facility in 2016. As of June 30, 2017 the entire facility under the Bancroft Lease has been subleased. During 2016, the Company established a letter of credit with Bank of America Merrill Lynch as security for the Heinz Lease in the amount of $0.5 million. The letter of credit is collateralized by a certificate of deposit for $0.5 million which has been included in restricted cash in the consolidated balance sheet as of June 30, 2017 and December 31, 2016. The Company also has office and laboratory space in Oss, the Netherlands, for employees of Aduro Biotech Europe. The term of the Oss lease is through December 2017, with a one-year renewal option. Rent expense was $1.6 million and $1.0 million for the three months ended June 30, 2017 and 2016, respectively, and $2.9 million and $1.2 million for the six months ended June 30, 2017 and 2016, respectively. Under the terms of the lease agreements, the Company is also responsible for certain insurance, property tax and maintenance expenses. Future minimum payments under the Company’s office leases at June 30, 2017 are as follows (in thousands): Year Ending December 31, Amounts 2017 (remaining six months) $ 1,991 2018 4,893 2019 4,669 2020 4,809 2021 4,953 Thereafter 43,672 Total $ 64,987 Indemnification In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance. Legal The Company is not party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of our business. Other Commitments The Company has various manufacturing, clinical, research and other contracts with vendors in the conduct of the normal course of its business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, generally the Company would only be obligated for the products or services that the Company had received at the time the termination became effective as well as non-cancelable and non-refundable obligations, including those incurred by the vendor for products or services before the termination became effective, and in some cases a termination fee. In the case of terminating a clinical trial agreement at a particular site, the Company may also be obligated to provide continued support for appropriate treatment for clinical trial subjects at that site until or after completion or termination.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity At-the-Market Sales Agreement In May 2016, the Company entered into an “at-the-market” sales agreement, or the 2016 Sales Agreement, with Cowen and Company, LLC, or Cowen, through which the Company may offer and sell shares of its common stock having an aggregate offering of up to $100.0 million from time to time through The issuance and sale of these shares by the Company pursuant to the 2016 Sales Agreement are deemed an “at-the-market” offering under the Securities Act of 1933, as amended. Under the 2016 Sales Agreement, the Company has agreed to pay Cowen a commission of up to 3% of the gross proceeds of any sales made pursuant to the Sales Agreement. During the six months ended June 30, 2017, the Company received net proceeds of $60.5 million after deducting commissions and expenses payable by the Company, from the sale of 5,823,789 shares of common stock pursuant to the 2016 Sales Agreement. Since the inception of the 2016 Sales Agreement through June 30, 2017, the Company has sold a total of 8,350,018 shares and received net total proceeds of $97.3 million. As of June 30, 2017 there were no amounts remaining for future sales under the Sales Agreement.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plans	9. Equity Incentive Plans 2015 Plan In March 2015, the Company’s board of directors adopted and in April 2015 the Company’s stockholders approved the 2015 Equity Incentive Plan, or the 2015 Plan, which became effective upon the Initial Public Offering (“IPO”) and provides for the granting of incentive stock options, nonstatutory stock options, and other forms of stock awards to its employees, directors and consultants. The Company’s 2009 Stock Incentive Plan, or the 2009 Plan, terminated on the date the 2015 Plan was adopted. Options granted or shares issued under the 2009 Plan that were outstanding on the date the 2015 Plan became effective will remain subject to the terms of the 2009 Plan. The 2015 Plan is administered by the board of directors or a committee appointed by the board of directors, which determines the types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The exercise price of incentive stock options and nonqualified stock options will be no less than 100% of the fair value per share of the Company’s common stock on the date of grant. If an individual owns capital stock representing more than 10% of the voting shares, the price of each share will be at least 110% of the fair value on the date of grant. Options expire after 10 years (five years for stockholders owning greater than 10% of the voting stock). The number of shares of common stock initially reserved for issuance under the 2015 Plan was 6,134,292 shares with an automatic annual increase to the shares issuable under the 2015 Plan to the lower of (i) 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (ii) a lower number determined by the board of directors. On January 1, 2017 the shares issuable under the 2015 Plan increased by 2,716,729. The Company had 6,826,585 shares available for future grant under the 2015 Plan as of June 30, 2017. 2009 Plan The Company’s 2009 Stock Incentive Plan, or the 2009 Plan, terminated on the date the 2015 Plan was adopted. Options granted or shares issued under the 2009 Plan that were outstanding on the date the 2015 Plan became effective will remain subject to the terms of the 2009 Plan. Prior to the 2009 Plan termination, the number of options available for grant was increased by 360,000 shares. At June 30, 2017, 6,649,962 options under the 2009 Plan remained outstanding. Stock Options The following table summarizes stock option activity for the six months ended June 30, 2017: Options Outstanding Shares Available for Grant Number of Options Weighted- Average Exercise Price Aggregate Intrinsic Value (In thousands) Balance—December 31, 2016 5,011,459 10,690,156 $ 6.65 $ 74,984 Authorized 2,716,729 — RSUs granted, net (92,500 ) — Granted (913,100 ) 913,100 10.74 Exercised (642,845 ) 0.78 Canceled 103,997 (1) (114,405 ) 17.46 Balance—June 30, 2017 6,826,585 10,846,006 $ 7.23 $ 68,779 Options exercisable—June 30, 2017 6,129,250 $ 4.88 $ 50,920 Options vested and expected to vest—June 30, 2017 10,622,133 $ 7.14 $ 68,244 (1) This excludes 10,408 canceled options for the six months ended June 30, 2017 initially granted from the legacy stock option plans. As these plans have been terminated, any options canceled are not added back to the existing option plan pool. The aggregate intrinsic value represents the difference between the exercise price of the options and the closing price of the Company’s common stock. The aggregate intrinsic value of options exercised for the three and six months ended June 30, 2017 was $4.1 million and $6.3 million, respectively. As of June 30, 2017, the total unrecognized compensation expense related to unvested options, net of estimated forfeitures, was $31.7 million, which the Company expects to recognize over an estimated weighted-average period of 2.3 years. Restricted Stock Units (RSUs) In September 2016, the Company’s board of directors authorized the issuance of Restricted Stock Units, or RSUs, under the 2015 Plan and adopted a form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement, or the RSU Agreement, which is intended to serve as a standard form agreement for restricted stock unit grants issued to employees, executive officers, directors and consultants. The following table summarizes restricted stock unit activity for the six months ended June 30, 2017: RSUs Outstanding Number of Restricted Units Weighted- Average Grant Date Fair Share Balance—December 31, 2016 657,200 $ 14.29 Granted 103,400 11.15 Canceled/forfeited (10,900 ) 14.29 Balance—June 30, 2017 749,700 $ 13.86 The fair value of RSUs is determined on the date of grant based on the market price of the Company’s common stock on that date. As of June 30, 2017, there was $7.8 million of unrecognized stock-based compensation expense, net of estimated forfeitures, related to RSUs to be recognized over a weighted-average period of 3.3 years. Stock-based Compensation Expense Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 2,343 $ 1,971 $ 4,593 $ 3,969 General and administrative 1,655 1,354 3,392 3,099 Total stock-based compensation expense $ 3,998 $ 3,325 $ 7,985 $ 7,068 In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model. The fair value of stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: 2015 Plan 2015 ESPP Six Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected term (in years) 5.31 - 6.04 2.00 - 6.05 0.5 0.5 Volatility 73.2 - 74.1% 73.0 - 75.0% 65.4% 73.8% Risk-free interest rate 1.78 - 2.25% 1.25 - 1.72% 1.02% 0.36% Dividend yield —% —% —% —% 2015 Employee Stock Purchase Plan In March 2015, the Company’s board of directors adopted and in April 2015 the Company’s stockholders approved the 2015 Employee Stock Purchase Plan, or 2015 ESPP, which became effective upon the IPO. The 2015 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the Code, and is administered by the Company’s board of directors and the Compensation Committee of the board of directors. The number of shares of common stock initially reserved for issuance under the 2015 ESPP was 720,000 shares with an automatic annual increase to the shares issuable under the 2015 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (ii) a lower number determined by the board of directors. On January 1, 2017 the shares issuable under the 2015 ESPP increased by 679,182. The Company had 1,838,166 shares available for future issuance under the 2015 ESPP as of June 30, 2017. Under the Aduro Biotech, Inc. Employee Stock Purchase Plan (“ESPP”) employees purchased 58,385 shares for $0.5 million during the six months ended June 30, 2017.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Income tax (benefit)/expense for the three months ended June 30, 2017 and 2016 was approximately $(3.8) million and $1.5 million, respectively, and $(6.5) million and $4.7 million for the six months ended June 30, 2017 and 2016, respectively. The income tax benefit recorded for the first half of 2017 primarily related to the current benefit of federal income taxes paid in 2016. The income tax expense recorded in 2016, primarily related to federal current and deferred income taxes. The Company accounts for uncertain tax positions in accordance with ASC 740 , Accounting for Income Taxes The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. As of June 30, 2017 and 2016, the Company accrued no interest and penalties in the statement of financial position. There were no interest and penalties included in the condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016. The Company does not expect the amount of existing unrecognized tax benefits to change significantly within the next 12 months. The Company files income tax returns in the United States and the Netherlands. The federal and state income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December 31, 2010 through December 31, 2016. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the IRS or state tax authorities to the extent utilized in a future period. For the Netherlands, the tax administration can impose an additional assessment within five years from the year in which the tax debt originated.

Net Income_Loss per Common Shar

Net Income/Loss per Common Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Income/Loss per Common Share	11. Net Income/Loss per Common Share Basic net income (loss) per share is calculated using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share gives effect to dilutive stock options and warrants. The Company uses the treasury-stock method to compute diluted earnings per share with respect to its stock options and warrants. The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Net income (loss) (19,400 ) $ 2,296 (41,211 ) $ (26,531 ) Shares used in computing basic net income (loss) per common share 71,101,336 64,434,903 69,679,746 64,138,737 Add effect of dilutive securities: Stock options — 6,949,706 — — Common stock warrants — 89,198 — — Shares used in computing diluted net income (loss) per common share 71,101,336 71,473,807 69,679,746 64,138,737 Net income (loss) per common share, basic $ (0.27 ) $ 0.04 $ (0.59 ) $ (0.41 ) Net income (loss) per common share, diluted $ (0.27 ) $ 0.03 $ (0.59 ) $ (0.41 ) Potentially dilutive securities that were not included in the diluted per common share calculations because they would be anti-dilutive were as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Options to purchase common stock 10,846,006 2,061,539 10,846,006 10,552,400 Restricted stock units 749,700 — 749,700 — Common stock warrants 95,221 2,664 95,221 97,621 Total 11,690,927 2,064,203 11,690,927 10,650,021

Basis of Presentation, Use of18

Basis of Presentation, Use of Estimates and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, and follow the requirements of the Securities and Exchange Commission, or the SEC, for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These financial statements have been prepared on the same basis as our annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for a fair presentation of our financial information. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or for any other interim period or for any other future year. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2016 included in our Annual Report on Form 10-K filed with the SEC. The consolidated financial statements include the accounts of Aduro Biotech, Inc. and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical trial accruals, contingent consideration, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board, or FASB, issued Auditing Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, which reduces the complexity when applying the guidance for identifying performance obligations and improves the operability and understandability of the license implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which amends the guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The new standard permits adoption either by using (i) a full retrospective approach for all periods presented in the period of adoption or (ii) a modified retrospective approach with the cumulative effect of initially applying the new standard recognized at the date of initial application and providing certain additional disclosures. The new standard is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted for annual reporting periods beginning after December 15, 2016. The Company plans to adopt the new standard effective January 1, 2018 and has not made the decision as to which adoption method it will utilize. The Company’s final determination will depend on the significance of the impact of the new standard on the Company’s financial results. The Company has completed the initial evaluation of the adoption of the new standard. This included the determination of whether the counterparty in its existing collaboration agreements met the definition of a customer and whether such agreements would be within the scope of the new standard. As a result, certain of the Company’s collaboration agreements are in scope and the Company is currently determining the impact that these agreements may have on its financial results. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments--Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company has evaluated the impact of this guidance and has concluded that adoption of the standard will not have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and, (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018 and requires modified retrospective application. Early adoption is permitted. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326). The standard changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the net amount expected to be collected by using an allowance for credit losses. The standard is effective for fiscal years and interim periods beginning after December 15, 2019. Early adoption is permitted for all periods beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows. The standard is effective for fiscal years and interim periods beginning after December 15, 2017. The standard should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company has evaluated the impact of this guidance and has concluded that the adoption of the standard will not have a material impact on its Consolidated Statement of Cash Flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that the statement of cash flows explains the change during the period in the total cash, cash equivalents, and restricted cash. The standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those years. This standard should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company plans to adopt this standard on January 1, 2018 utilizing the required retrospective transition method. The adoption of ASU 2016-18 on January 1, 2018 will change the presentation and classification of restricted cash in our Consolidated Statement of Cash Flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 provides clarity and reduces the complexity of applying the guidance in Topic 718, Compensation – Stock Compensation, to a change to the terms or conditions of a share-based payment award. This standard is effective for annual periods beginning after December 15, 2017. The Company is currently in the process of evaluating the impact that the standard will have on its consolidated financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeitures. Formerly, these excess tax benefits were recognized in additional paid-in capital and tax deficiencies (to the extent there were previous tax benefits) were recognized as an offset to accumulated excess tax benefits. If no previous tax benefit existed, the deficiencies were recognized in the income statement as an increase to income tax expense. The changes require all excess tax benefits and tax deficiencies related to share-based payments be recognized as income tax expense or benefit in the income statement. Gross excess tax benefits in the cash flow statement have also changed from the prior presentation as a financing activity to being classified as an operating activity. The excess tax benefits are no longer included in the assumed proceeds of the diluted EPS calculation, which results in stock-based awards being more dilutive. Lastly, the Company elected to continue to estimate forfeitures based on historical data and recognizes forfeiture compensation expense over the vesting period of the award. This standard is effective prospectively for annual reporting periods, and interim periods therein, beginning after December 15, 2016. The Company adopted this ASU on January 1, 2017 which resulted in the recognition of excess tax benefits within the Condensed Consolidated Statements of Operations rather than paid-in capital of $1.8 million for the six months ended June 30, 2017.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): June 30, 2017 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 52,650 $ — $ — $ 52,650 U.S. government and agency securities — 116,114 — 116,114 Corporate debt securities — 71,222 — 71,222 Commercial paper — 124,235 — 124,235 Total $ 52,650 $ 311,571 $ — $ 364,221 Financial Liabilities: Contingent consideration related to acquisition $ — $ — $ 6,044 $ 6,044 Total $ — $ — $ 6,044 $ 6,044 December 31, 2016 Level 1 Level 2 Level 3 Total Financial Assets: Money market funds $ 54,318 $ — $ — $ 54,318 U.S. government and agency securities — 166,800 — 166,800 Corporate debt securities — 77,880 — 77,880 Commercial paper — 49,643 — 49,643 Total $ 54,318 $ 294,323 $ — $ 348,641 Financial Liabilities: Contingent consideration related to acquisition $ — $ — $ 4,032 $ 4,032 Total $ — $ — $ 4,032 $ 4,032
Summary of Changes in Fair Value of Level 3 Financial Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands): Contingent Consideration Balance at December 31, 2016 $ 4,032 Net change in fair value upon remeasurement 1,636 Foreign currency impact on contingent consideration 376 Balance at June 30, 2017 $ 6,044
Summary of Estimated Value of Cash, Cash Equivalents and Marketable Securities and Gross Unrealized Holding Gains and Losses	The following tables summarize the estimated value of the Company’s cash, cash equivalents and marketable securities and the gross unrealized holding gains and losses (in thousands): June 30, 2017 Amortized cost Unrealized gains Unrealized losses Estimated Fair Value Cash and cash equivalents: Cash $ 13,022 $ — $ — $ 13,022 Money market funds 52,650 — — 52,650 U.S. government and agency securities 40,735 1 (1 ) 40,735 Commercial paper 77,408 — — 77,408 Total cash and cash equivalents $ 183,815 $ 1 $ (1 ) $ 183,815 Marketable securities: U.S. government and agency securities $ 75,457 $ — $ (78 ) $ 75,379 Corporate debt securities 71,284 — (62 ) 71,222 Commercial paper 46,827 — — 46,827 Total marketable securities $ 193,568 $ — $ (140 ) $ 193,428 December 31, 2016 Amortized cost Unrealized gains Unrealized losses Estimated Fair Value Cash and cash equivalents: Cash $ 13,265 $ — $ — $ 13,265 Money market funds 54,318 — — 54,318 Commercial paper 7,349 — — 7,349 Total cash and cash equivalents $ 74,932 $ — $ — $ 74,932 Marketable securities: U.S. government and agency securities $ 166,854 $ 7 $ (61 ) $ 166,800 Corporate debt securities 77,967 — (87 ) 77,880 Commercial paper 42,294 — 42,294 Total marketable securities $ 287,115 $ 7 $ (148 ) $ 286,974
Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity	The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities by contractual maturity are summarized below as of June 30, 2017 (in thousands): Amortized cost Estimated Fair Mature in one year or less $ 193,568 $ 193,428 Total available-for-sale marketable securities $ 193,568 $ 193,428

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2017
Balance Sheet Components [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): June 30, December 31, 2017 2016 Lab equipment $ 6,571 $ 5,379 Computer and office equipment 1,816 1,755 Furniture and fixtures 1,731 1,479 Leasehold improvements 17,968 17,473 Construction in progress 3,588 3,930 Total property and equipment 31,674 30,016 Less: accumulated depreciation and amortization (5,314 ) (3,632 ) Property and equipment, net $ 26,360 $ 26,384
Accrued Expenses and Other Liabilities	Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following (in thousands): June 30, December 31, 2017 2016 Compensation and related benefits $ 3,101 $ 4,228 Professional and consulting services 1,586 1,168 Deferred rent, current portion 421 331 Accrued research expense 775 489 Income tax payable — 806 Other 1,190 1,575 Total accrued expenses and other liabilities $ 7,073 $ 8,597

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The gross carrying amount of goodwill was as follows (in thousands): Balance at December 31, 2016 $ 7,658 Foreign currency translation adjustment 660 Balance at June 30, 2017 $ 8,318
Schedule of Intangible Assets	The gross carrying amounts and net book value of our intangible assets were as follows (in thousands): June 30, 2017 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: License agreement $ 11,297 $ 941 $ 10,356 Total intangible assets with finite lives 11,297 941 10,356 Acquired IPR&D assets 19,590 — 19,590 Total intangible assets $ 30,887 $ 941 $ 29,946 December 31, 2016 Gross Amount Accumulated Amortization Net Book Value Intangible assets with finite lives: License agreement $ 10,400 $ 607 $ 9,793 Total intangible assets with finite lives 10,400 607 9,793 Acquired IPR&D assets 18,034 — 18,034 Total intangible assets $ 28,434 $ 607 $ 27,827
Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense	Based on finite-lived intangible assets recorded as of June 30, 2017, the estimated future amortization expense is as follows (in thousands): Year Ending December 31, Estimated Amortization Expense 2017 (remaining six months) $ 282 2018 565 2019 565 2020 565 2021 565

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments under the Company's Office Leases	Future minimum payments under the Company’s office leases at June 30, 2017 are as follows (in thousands): Year Ending December 31, Amounts 2017 (remaining six months) $ 1,991 2018 4,893 2019 4,669 2020 4,809 2021 4,953 Thereafter 43,672 Total $ 64,987

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	Stock Options The following table summarizes stock option activity for the six months ended June 30, 2017: Options Outstanding Shares Available for Grant Number of Options Weighted- Average Exercise Price Aggregate Intrinsic Value (In thousands) Balance—December 31, 2016 5,011,459 10,690,156 $ 6.65 $ 74,984 Authorized 2,716,729 — RSUs granted, net (92,500 ) — Granted (913,100 ) 913,100 10.74 Exercised (642,845 ) 0.78 Canceled 103,997 (1) (114,405 ) 17.46 Balance—June 30, 2017 6,826,585 10,846,006 $ 7.23 $ 68,779 Options exercisable—June 30, 2017 6,129,250 $ 4.88 $ 50,920 Options vested and expected to vest—June 30, 2017 10,622,133 $ 7.14 $ 68,244 (1) This excludes 10,408 canceled options for the six months ended June 30, 2017 initially granted from the legacy stock option plans. As these plans have been terminated, any options canceled are not added back to the existing option plan pool.
Summary of Restricted Stock Unit Activity	The following table summarizes restricted stock unit activity for the six months ended June 30, 2017: RSUs Outstanding Number of Restricted Units Weighted- Average Grant Date Fair Share Balance—December 31, 2016 657,200 $ 14.29 Granted 103,400 11.15 Canceled/forfeited (10,900 ) 14.29 Balance—June 30, 2017 749,700 $ 13.86
Summary of Stock-Based Compensation	Total stock-based compensation expense recognized was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 2,343 $ 1,971 $ 4,593 $ 3,969 General and administrative 1,655 1,354 3,392 3,099 Total stock-based compensation expense $ 3,998 $ 3,325 $ 7,985 $ 7,068
Schedule of Black-Scholes Option-Pricing Model	The fair value of stock option awards granted to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: 2015 Plan 2015 ESPP Six Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Expected term (in years) 5.31 - 6.04 2.00 - 6.05 0.5 0.5 Volatility 73.2 - 74.1% 73.0 - 75.0% 65.4% 73.8% Risk-free interest rate 1.78 - 2.25% 1.25 - 1.72% 1.02% 0.36% Dividend yield —% —% —% —%

Net Income_Loss per Common Sh24

Net Income/Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Net Income (Loss) per Share	The following table sets forth a reconciliation of basic and diluted net income (loss) per share (in thousands except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Net income (loss) (19,400 ) $ 2,296 (41,211 ) $ (26,531 ) Shares used in computing basic net income (loss) per common share 71,101,336 64,434,903 69,679,746 64,138,737 Add effect of dilutive securities: Stock options — 6,949,706 — — Common stock warrants — 89,198 — — Shares used in computing diluted net income (loss) per common share 71,101,336 71,473,807 69,679,746 64,138,737 Net income (loss) per common share, basic $ (0.27 ) $ 0.04 $ (0.59 ) $ (0.41 ) Net income (loss) per common share, diluted $ (0.27 ) $ 0.03 $ (0.59 ) $ (0.41 )
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Per Common Share	Potentially dilutive securities that were not included in the diluted per common share calculations because they would be anti-dilutive were as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Options to purchase common stock 10,846,006 2,061,539 10,846,006 10,552,400 Restricted stock units 749,700 — 749,700 — Common stock warrants 95,221 2,664 95,221 97,621 Total 11,690,927 2,064,203 11,690,927 10,650,021

Organization and Nature of Bu25

Organization and Nature of Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2017SegmentPlatform
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of business segments | Segment	1
Number of technology platforms | Platform	3

Basis of Presentation, Use of26

Basis of Presentation, Use of Estimates and Recent Accounting Pronouncements - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
ASU 2016-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Recognition of excess tax benefits for stock-based compensation	$ 1.8

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Financial Assets:
Financial Assets, fair value	$ 364,221	$ 348,641
Financial Liabilities:
Financial Liabilities, fair value	6,044	4,032
Contingent Consideration Related To Acquisition
Financial Liabilities:
Financial Liabilities, fair value	6,044	4,032
Money Market Funds
Financial Assets:
Financial Assets, fair value	52,650	54,318
U S Government Agencies Debt Securities
Financial Assets:
Financial Assets, fair value	116,114	166,800
Corporate Debt Securities
Financial Assets:
Financial Assets, fair value	71,222	77,880
Commercial Paper
Financial Assets:
Financial Assets, fair value	124,235	49,643
Level 1
Financial Assets:
Financial Assets, fair value	52,650	54,318
Level 1 | Money Market Funds
Financial Assets:
Financial Assets, fair value	52,650	54,318
Level 2
Financial Assets:
Financial Assets, fair value	311,571	294,323
Level 2 | U S Government Agencies Debt Securities
Financial Assets:
Financial Assets, fair value	116,114	166,800
Level 2 | Corporate Debt Securities
Financial Assets:
Financial Assets, fair value	71,222	77,880
Level 2 | Commercial Paper
Financial Assets:
Financial Assets, fair value	124,235	49,643
Level 3
Financial Liabilities:
Financial Liabilities, fair value	6,044	4,032
Level 3 | Contingent Consideration Related To Acquisition
Financial Liabilities:
Financial Liabilities, fair value	$ 6,044	$ 4,032

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair value assets transferred from level 1 to level 2	$ 0	$ 0
Fair value assets transferred from level 2 to level 1	0	0
Fair value liabilities transferred from level 1 to level 2	0	0
Fair value liabilities transferred from level 2 to level 1	0	0
Fair value assets transferred into level 3	0	0
Fair value assets transferred out of level 3	0	0
Fair value liabilities transferred into level 3	0	0
Fair value liabilities transferred out of level 3	0	0
Financial assets measured at fair value on a nonrecurring basis	0	0
Financial liabilities measured at fair value on a nonrecurring basis	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Liabilities (Details) - Contingent Consideration $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance	$ 4,032
Net change in fair value upon remeasurement	1,636
Foreign currency impact on contingent consideration	376
Ending balance	$ 6,044

Fair Value Measurements - Sum30

Fair Value Measurements - Summary of Estimated Value of Cash, Cash Equivalents and Marketable Securities and Gross Unrealized Holding Gains and Losses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized cost	$ 183,815	$ 74,932
Cash and cash equivalents, Unrealized gains	1
Cash and cash equivalents, Unrealized losses	(1)
Cash and cash equivalents, Estimated Fair Value	183,815	74,932
Marketable securities, Amortized cost	193,568	287,115
Marketable securities, Unrealized gains		7
Marketable securities, Unrealized losses	(140)	(148)
Marketable securities, Estimated Fair Value	193,428	286,974
Cash
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized cost	13,022	13,265
Cash and cash equivalents, Estimated Fair Value	13,022	13,265
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized cost	52,650	54,318
Cash and cash equivalents, Estimated Fair Value	52,650	54,318
U.S. Government and Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized cost	40,735
Cash and cash equivalents, Unrealized gains	1
Cash and cash equivalents, Unrealized losses	(1)
Cash and cash equivalents, Estimated Fair Value	40,735
Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, Amortized cost	77,408	7,349
Cash and cash equivalents, Estimated Fair Value	77,408	7,349
U S Government Agencies Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, Amortized cost	75,457	166,854
Marketable securities, Unrealized gains		7
Marketable securities, Unrealized losses	(78)	(61)
Marketable securities, Estimated Fair Value	75,379	166,800
Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, Amortized cost	71,284	77,967
Marketable securities, Unrealized losses	(62)	(87)
Marketable securities, Estimated Fair Value	71,222	77,880
Commercial paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, Amortized cost	46,827	42,294
Marketable securities, Estimated Fair Value	$ 46,827	$ 42,294

Fair Value Measurements - Sum31

Fair Value Measurements - Summary of Amortized Cost and Estimated Fair Value of Available-for-Sale Marketable Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Mature in one year or less, Amortized cost	$ 193,568
Marketable securities, Amortized cost	193,568	$ 287,115
Mature in one year or less, Estimated Fair Value	193,428
Marketable securities, Estimated Fair Value	$ 193,428	$ 286,974

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 31,674	$ 30,016
Less: accumulated depreciation and amortization	(5,314)	(3,632)
Property and equipment, net	26,360	26,384
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,571	5,379
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,816	1,755
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,731	1,479
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	17,968	17,473
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,588	$ 3,930

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Balance Sheet Components [Abstract]
Depreciation and amortization	$ 833	$ 382	$ 1,659	$ 739

Balance Sheet Components - Su34

Balance Sheet Components - Summary of Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Compensation and related benefits	$ 3,101	$ 4,228
Professional and consulting services	1,586	1,168
Deferred rent, current portion	421	331
Accrued research expense	775	489
Income tax payable		806
Other	1,190	1,575
Total accrued expenses and other liabilities	$ 7,073	$ 8,597

Goodwill and Intangible Asset35

Goodwill and Intangible Assets - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Balance at December 31, 2016	$ 7,658
Foreign currency translation adjustment	660
Balance at June 30, 2017	$ 8,318

Goodwill and Intangible Asset36

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	$ 11,297	$ 10,400
Finite Lived Intangible Assets, Accumulated Amortization	941	607
Finite Lived Intangible Assets, Net Book Value	10,356	9,793
Intangible Assets, Gross Carrying Amount	30,887	28,434
Intangible assets, Net Book Value	29,946	27,827
License agreement
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Gross Carrying Amount	11,297	10,400
Finite Lived Intangible Assets, Accumulated Amortization	941	607
Finite Lived Intangible Assets, Net Book Value	10,356	9,793
Acquired IPR&D assets
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets, Gross Carrying Amount	$ 19,590	$ 18,034

Goodwill and Intangible Asset37

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible assets, amortization period			20 years
Amortization of intangible assets	$ 136	$ 140	$ 268	$ 277

Goodwill and Intangible Asset38

Goodwill and Intangible Assets - Schedule of Finite-Lived Intangible Assets Estimated Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2017 (remaining six months)	$ 282
2,018	565
2,019	565
2,020	565
2,021	$ 565

Collaboration Agreements - Addi

Collaboration Agreements - Additional Information (Details)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

18 Months Ended

32 Months Ended

38 Months Ended

Jul. 31, 2015

Apr. 30, 2015USD ($)

Feb. 28, 2015Product

May 31, 2014USD ($)

Jun. 30, 2017USD ($)

Jun. 30, 2016USD ($)

Jun. 30, 2017USD ($)

Jun. 30, 2016USD ($)

Dec. 31, 2015USD ($)

Oct. 31, 2015USD ($)

Oct. 31, 2015USD ($)

Jun. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Dec. 31, 2016USD ($)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue

$ 14,945,000

$ 14,945,000

$ 14,945,000

$ 14,945,000

$ 15,052,000

Duo Body Product

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Number of product candidates | Product

5

Percentage of development cost share

50.00%

Novartis Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Novartis share of joint development costs

38.00%

Period after first commercial sale of product on which Novartis' royalty obligation run on a country to country basis

12 years

Estimated performance period of agreement

13 years 6 months

Revenue recognized

3,800,000

$ 3,700,000

$ 7,500,000

$ 7,400,000

Deferred revenue

170,400,000

$ 170,400,000

170,400,000

170,400,000

Novartis Agreement | United States

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborative arrangement profit share percentage

50.00%

Novartis Agreement | European Countries and Japan

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborative arrangement profit share percentage

45.00%

Novartis Agreement | United States, Specified European Countries and /or Japan

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Collaborative Agreement, Obligations

With respect to the United States, specified European countries and/or Japan, the Company may elect for such region to either reduce by 50% or to eliminate in full the Company’s development and commercialization cost sharing obligation. If the Company elects to reduce its cost sharing percentage by 50% in any such region, then its profit share in such region will also be reduced by 50%. If the Company elects to eliminate its development cost sharing obligation, then such region will be removed from the profit share, and instead Novartis will owe the Company royalties on any net sales of product for such region, as described above.

Reduction percentage of development cost share

50.00%

Reduction percentage of profit share

50.00%

Novartis Agreement | Novartis

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Novartis share of joint development costs

62.00%

Collaborative arrangement profit share percentage

50.00%

Novartis Agreement | Up Front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 200,000,000

Novartis Agreement | Development Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Revenue recognized for milestones

$ 35,000,000

Novartis Agreement | Maximum | Development Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive

$ 215,000,000

Novartis Agreement | Maximum | Regulatory Approval Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive

250,000,000

Janssen ADU-214 Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Revenue recognized for milestones

$ 21,000,000

Janssen ADU-214 Agreement | Up Front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 30,000,000

30,000,000

Janssen ADU-214 Agreement | Non Substantive And Substantive Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 21,000,000

Janssen ADU-214 Agreement | Maximum | Contingent Payments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive

766,000,000

Janssen ADU-741 Agreements | Up Front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

12,000,000

Janssen ADU-741 Agreements | Non Substantive And Substantive Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 10,000,000

Janssen ADU-741 Agreements | Maximum | Contingent Payments

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive

343,000,000

Janssen GVAX Prostate Agreement | Up Front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 500,000

Janssen GVAX Prostate Agreement | Specified Commercial Milestone

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive

2,000,000

Janssen ADU-741 and Janssen GVAX Prostate Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Revenue recognized for milestones

$ 10,000,000

Janssen ADU-741 and Janssen GVAX Prostate Agreement | Up Front Payment Arrangement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Payments received under collaboration agreement

$ 12,500,000

Merck License Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Revenue recognized for milestones

$ 2,000,000

Merck License Agreement | Maximum | Development Milestone Contingent Payments | Product Candidate

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive for products or product candidates

310,000,000

Merck License Agreement | Maximum | Commercial And Net Sales Contingent Milestone Payments | Product

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Milestone amount eligible to receive for products or product candidates

$ 135,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)ft²	Jun. 30, 2017USD ($)LeaseTermRenewalOption	Jun. 30, 2016USD ($)ft²	Dec. 31, 2016USD ($)	Mar. 31, 2016ft²	Feb. 28, 2015ft²
Operating Leased Assets [Line Items]
Total square footage of leased property | ft²							25,000
Additional operating lease term			2 years
Lease expiration date			Dec. 31, 2018
Security deposit	$ 500,000		$ 500,000		$ 500,000
Restricted cash	468,000		468,000		468,000
Rent expense	1,600,000	$ 1,000,000	2,900,000	$ 1,200,000
Letter of Credit | Bank Of America Merrill Lynch
Operating Leased Assets [Line Items]
Line of credit facility, maximum borrowing capacity					500,000
Collateral Pledged | Certificates of Deposit | Letter of Credit | Bank Of America Merrill Lynch
Operating Leased Assets [Line Items]
Restricted cash	$ 500,000		$ 500,000		$ 500,000
Office Laboratory Lease
Operating Leased Assets [Line Items]
Total square footage of leased property | ft²						56,000
Description of lease			The Company began incurring rent expense when the landlord delivered possession of the facility to the Company
Operating lease initial term			12 years
Operating lease extended term			13 years 6 months
Operating lease commencement date			2016-03
Operating lease, additional space | ft²		7,000
Additional lease option rights exercised | ft²		41,000		41,000
Number of additional renewal terms | LeaseTerm			2
Additional operating lease term			5 years
Office Laboratory Lease | Netherlands
Operating Leased Assets [Line Items]
Operating leases term of expiration			2017-12
Number of renewal options for operating leases | RenewalOption			1

Commitments and Contingencies41

Commitments and Contingencies - Schedule of Future Minimum Payments under the Company's Office Leases (Details) $ in Thousands	Jun. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2017 (remaining six months)	$ 1,991
2,018	4,893
2,019	4,669
2,020	4,809
2,021	4,953
Thereafter	43,672
Total	$ 64,987

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	1 Months Ended	6 Months Ended	14 Months Ended
	May 31, 2016	Jun. 30, 2017	Jun. 30, 2017
Stockholders' Equity [Line Items]
Net proceeds from issuance of common stock, after deducting commissions and expenses payable		$ 60,467,000
At-the-Market Offering | 2016 Sales Agreement | Cowen and Company, LLC
Stockholders' Equity [Line Items]
Commission on sales of common stock, percentage	3.00%
Issuance of common stock (in shares)		5,823,789	8,350,018
Net proceeds from issuance of common stock, after deducting commissions and expenses payable		$ 60,500,000	$ 97,300,000
Amounts remaining for future sales		$ 0	$ 0
At-the-Market Offering | 2016 Sales Agreement | Cowen and Company, LLC | Maximum
Stockholders' Equity [Line Items]
Aggregate offering from offer and sell of common stock	$ 100,000,000

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($) $ in Millions	Jan. 01, 2017	Feb. 28, 2015	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016	Apr. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issuable increased during the period				2,716,729
Number of shares available for future grant			6,826,585	6,826,585	5,011,459
Number of options outstanding			10,846,006	10,846,006	10,690,156
Aggregate intrinsic value of options exercised			$ 4.1	$ 6.3
Unrecognized compensation expense			31.7	$ 31.7
Weighted-average period of unrecognized compensation expense				2 years 3 months 18 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average period of unrecognized compensation expense				3 years 3 months 18 days
Unrecognized stock-based compensation expense related to RSUs			$ 7.8	$ 7.8
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price to fair market value common stock on grant date				100.00%
Stock option expiration period				10 years
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares reserved for issuance						6,134,292
Percentage of shares issued on common stock outstanding				4.00%
Common Stock Issuance Description				shares issuable under the 2015 Plan to the lower of (i) 4% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (ii) a lower number determined by the board of directors.
Shares issuable increased during the period	2,716,729
Number of shares available for future grant			6,826,585	6,826,585
2009 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issuable increased during the period		360,000
Number of options outstanding			6,649,962	6,649,962
2015 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares reserved for issuance						720,000
Percentage of shares issued on common stock outstanding				1.00%
Common Stock Issuance Description				shares issuable under the 2015 ESPP to the lower of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (ii) a lower number determined by the board of directors.
Shares issuable increased during the period	679,182
Number of shares available for future grant			1,838,166	1,838,166
Shares purchased by employees				58,385
Shares purchased by employees, value				$ 0.5
More Than 10% Voting Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option expiration period				5 years
More Than 10% Voting Shares | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of exercise price to fair market value common stock on grant date				110.00%

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Shares Available for Grant, Beginning balance	5,011,459
Options Outstanding, Shares Available for Grant, Authorized	2,716,729
Options Outstanding, Shares Available for Grant, RSUs granted, net	(92,500)
Options Outstanding, Shares Available for Grant, Granted	(913,100)
Options Outstanding, Shares Available for Grant, Canceled	103,997
Options Outstanding, Shares Available for Grant, Ending balance	6,826,585
Options Outstanding, Number of Options, Beginning balance	10,690,156
Options Outstanding, Number of Options, Granted	913,100
Options Outstanding, Number of Options, Exercised	(642,845)
Options Outstanding, Number of Options, Canceled	(114,405)
Options Outstanding, Number of Options, Ending balance	10,846,006
Options Outstanding, Number of Options, Options exercisable	6,129,250
Options Outstanding, Number of Options, Options vested and expected to vest	10,622,133
Options Outstanding, Weighted-Average Exercise Price, Beginning balance	$ 6.65
Options Outstanding, Weighted-Average Exercise Price, Granted	10.74
Options Outstanding, Weighted-Average Exercise Price, Exercised	0.78
Options Outstanding, Weighted-Average Exercise Price, Canceled	17.46
Options Outstanding, Weighted-Average Exercise Price, Ending balance	7.23
Options Outstanding, Weighted-Average Exercise Price, Options exercisable	4.88
Options Outstanding, Weighted-Average Exercise Price, Options vested and expected to vest	$ 7.14
Options Outstanding, Aggregate Intrinsic Value, Balance	$ 68,779	$ 74,984
Options Outstanding, Aggregate Intrinsic Value, Options exercisable—June 30, 2017	50,920
Options Outstanding, Aggregate Intrinsic Value, Options vested and expected to vest—June 30, 2017	$ 68,244

Equity Incentive Plans - Summ45

Equity Incentive Plans - Summary of Stock Option Activity (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2017shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of canceled options excluded	10,408

Equity Incentive Plans - Summ46

Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock Units, Beginning balance | shares	657,200
Number of Restricted Stock Units, Granted | shares	103,400
Number of Restricted Stock Units, Canceled/forfeited | shares	(10,900)
Number of Restricted Stock Units, Ending balance | shares	749,700
Weighted-Average Grant Date Fair Value Per Share, Beginning balance | $ / shares	$ 14.29
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	11.15
Weighted-Average Grant Date Fair Value Per Share, Canceled/forfeited | $ / shares	14.29
Weighted-Average Grant Date Fair Value Per Share, Ending balance | $ / shares	$ 13.86

Equity Incentive Plans - Summ47

Equity Incentive Plans - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,998	$ 3,325	$ 7,985	$ 7,068
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	2,343	1,971	4,593	3,969
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,655	$ 1,354	$ 3,392	$ 3,099

Equity Incentive Plans - Schedu

Equity Incentive Plans - Schedule of Black-Scholes Option-Pricing Model (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
2015 ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 months	6 months
Volatility	65.40%	73.80%
Risk-free interest rate	1.02%	0.36%
Minimum | 2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 3 months 22 days	2 years
Volatility	73.20%	73.00%
Risk-free interest rate	1.78%	1.25%
Maximum | 2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 15 days	6 years 18 days
Volatility	74.10%	75.00%
Risk-free interest rate	2.25%	1.72%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Tax Contingency [Line Items]
Income tax (benefit)/expense	$ (3,788,000)	$ 1,472,000	$ (6,540,000)	$ 4,698,000
Unrecognized tax benefits	2,800,000		2,800,000		$ 2,500,000
Amount of unrecognized tax benefits that would, if recognized, reduce effective tax rate	1,100,000		1,100,000		$ 1,100,000
Unrecognized tax benefits, income tax penalties and interest accrued	0	0	0	0
Unrecognized tax benefits, income tax penalties and interest expense	$ 0	$ 0	$ 0	$ 0
State and Local Jurisdiction | Earliest Tax Year
Income Tax Contingency [Line Items]
Open tax year			Dec. 31, 2010
State and Local Jurisdiction | Latest Tax Year
Income Tax Contingency [Line Items]
Open tax year			Dec. 31, 2016
U.S. Federal Tax Authority | Earliest Tax Year
Income Tax Contingency [Line Items]
Open tax year			Dec. 31, 2010
U.S. Federal Tax Authority | Latest Tax Year
Income Tax Contingency [Line Items]
Open tax year			Dec. 31, 2016
California Tax Authority
Income Tax Contingency [Line Items]
Tax assessment additional period			5 years

Net Income_Loss per Common Sh50

Net Income/Loss per Common Share - Reconciliation of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net (loss) income	$ (19,400)	$ 2,296	$ (41,211)	$ (26,531)
Shares used in computing basic net income (loss) per common share	71,101,336	64,434,903	69,679,746	64,138,737
Add effect of dilutive securities:
Stock options		6,949,706
Common stock warrants		89,198
Shares used in computing diluted net income (loss) per common share	71,101,336	71,473,807	69,679,746	64,138,737
Net income (loss) per common share, basic	$ (0.27)	$ 0.04	$ (0.59)	$ (0.41)
Net income (loss) per common share, diluted	$ (0.27)	$ 0.03	$ (0.59)	$ (0.41)

Net Income_Loss per Common Sh51

Net Income/Loss per Common Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Per Common Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per common share	11,690,927	2,064,203	11,690,927	10,650,021
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per common share	10,846,006	2,061,539	10,846,006	10,552,400
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per common share	749,700		749,700
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from diluted net loss per common share	95,221	2,664	95,221	97,621